Development of [111In]-DTPA-buserelin for GnRH receptor studies

Radiochimica Acta

Volumn 98, Issue 2, 2010, Pages 113-119

  Jalilian, A R ^a   Shanehsazzadeh, S ^b   Akhlaghi, M ^a   Kamali Dehghan, M ^a   Moradkhani, S ^a  

^a AGRICULTURAL MEDICAL AND INDUSTRIAL RESEARCH SCHOOL   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Arginine conjugation; Biodistribution; Buserelin; Indium 111; MCF 7; SPECT

Indexed keywords

EID: 77956209781     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2010.1689     Document Type: Article

References (39)

1. Schally, A. V., Arimura, A., Baba, Y., Nair, R. M., Matsuo, H., Redding, T. W., Debeljuk, L.: Isolation and properties of the FSH and Lll-releasing hormone. Biochem. Biophys. Res. Commun. 43, 393-399(1971).
2. Matsuo, H., Baba, Y., Nair, R. M., Arimura, A., Schally, A. V.: Biochem. Biophys. Res. Commun. 43, 1334-1339 (1971).
3. Baba, Y., Matsuo, H., Schally, A. V.: Structure of the porcine LH and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochem. Biophys. Res. Commun. 44, 459-463 (1971).
4. Fink, G.: Gonadotropin secretion and its control. In: The Physiology of Reproduction. (Knobil, E., Neill, J., eds.) Raven Press, New York (1988), pp. 1349-1377.
5. Seeburg, P. H., Mason, A. J., Stewart, T. A., Nikolics, K.: The mammalian GnRH gene and its pivotal role in reproduction. Recent. Prog. Ilorm. Res. 43, 69-98 (1987).
6. Tolis, G., Ackman, U., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T. A., Comaru-Schally, A. M., Schally, A. V.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA 79. 1658-1662 (1982).
7. Klijn, J. G. M.: Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med. Oncol. Tumor Pharrnacother. 1, 123-128 (1984).
8. Manni, A., Santen, R., Harvey, H., Lipton, A., Max, D.: Treatment of breast cancer with gonadotropin-releasing hormone. Endocr. Rev. 7, 89-94 (1986).
9. Reshkin, S. L., Pezzetta, A., Albarani, V., Schittulli, F., Paradiso, A.: Characterization of a 3H-GnRII method for the measurement of GnRH binding sites in human breast cancer and breast cancer cell lines. Int. J. Oncol. 7, 371-375 (1995).
10. Fekete, M., Wittliff, J. L., Schally, A. V.: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3, 137-147 (1989).
11. Paradiso, A., Pezzetta, A., Cellamare, G., Schittulli, F., Marzullo, F., Reshkin, S. J.: GnRH receptors in human breast cancer and its contiguous not-involved breast tissue. J. Endocrinol. Invest. 23, 90-96 (2000).
12. Srkalovic, G., Wittliff, J. L., Schally, A. V.: Detection and partial characterization of receptors for (D-Trp6)-luteinizing-hormone releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res. 50, l841-1846 (1990).
13. Etnons, G., Pahwa, G. S., Brack, G., Sturm, R., Oberheuser, E., Knupperi, R.: Gonadotrophin-releasing-hormone binding sites in human epithelial ovarian carcinoma. Eur. J. Cancer. Clin. Oncol. 25, 215-221 (1989).
14. Fekete, M., Zalatmai, A., Comaru-Schally, A. M., Schally, A. V.: Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4, 521-528 (1989).
15. Eidne, K. A., Flanagan, C. A., Harris, N. S., Millar, R. P.: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J. Clin. Endocrinol. Metab. 64, 425-432 (1987).
16. Miller, W. R., Scott, W. N., Morris, R., Fraser, H. M., Sharpe, R. M.: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231-233 (1985).
17. Flanagan, C. A., Fromrne, B. J., Davidson, J. S., Millar, R. P.: A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors. Endocrinology 139, 4115-4119 (1998).
18. Grzegorzewski, W. J., Skipor, J., Wasowska, B, Krzymowski, T.: Countercurrent transfer of l25I-LHRH in the peri hypophyseal cavernous sinus-carotid rete vascular complex, demonstrated on isolated pig heads perfused with autologous blood. Domest, Anim. Endocrinol. 14. 149-160 (1997).
19. Huang, Y. P., Ouo, D. C., Peter, R. E.: Isolation and characterization of a gonadotropin-releasing hormone binding protein in goldfish serum. Gen. Comp. Endocrinol. 84, 58-66 (1991).
20. Fasano, S., de Leeuw, R., Pierantoni, R., Chieffi, G., van Oordt, P. G.: Characterization of gonadotropin-releasing hormone (GnRH) binding sites in the pituitary and testis of the frog, Rana esculenta. Biochem. Biophys. Res. Commun. 168, 923-932 (1990).
21. Huckle, W. R., McArdle, C. A., Conn, P. M.: Differential sensitivity of agonist- and antagonist-occupied gonadotropin-releasing hormone receptors to protein kinase C activators, A marker for receptor activation. J. Biol. Chem. 263, 3296-302 (1988).
22. Barda, Y., Cohen, N., Lev, V., Ben-Aroya, N., Koch, Y., Mishani, E., Fridkin, M., Gilon, C.: Backbone metal cyclization: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. Nucl. Med. Biol. 31, 92133 (2004).
23. Engel, J. B., Schally, A. V., Engel, J. B.: Drag insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat. Clin. Pract. Endocrinol. Metab. 3, 157-167 (2007).
24. http://www.emea.europa.eu/pdfs/vet/mrls/gonadotrophin.pdf.
25. Mirzaii, M., Afarideh, H., Haji-Saied, S. M., Ardaneh, K.: Production of 111In by irradiation of natural cadmium with deuterons and protons in NRCAM cyclotron. In: Proc on 15th Int. Conf. on Cyclotrons and Their Applications. Caen, France (1998), pp. 65-67.
26. Marczenko, Z.: Spectrophotometry Determination of Elements. John Wiley & Sons Inc., New York (1976), Chapt. 12, pp. 176- 179.
27. Hnatowich, D. J., Layne, W. W., Childs, R. L., Lanteigne, D., Davis, M. A., Griffin, T. W., Dohcrty, P. W.: Radioactive labeling of antibody: a simple and efficient method. Science 220. 613-615 (1983).
28. Green, M. A., Welch, M. J.: Gallium radiopharmaceutical chemistry. Int. J. Rad. Appl. Instrum. B 16, 435-448 (1989), review.
29. Lindmo, T., Boven, E., Cuttitta, E., Fedorko, J., Bunn, P. A.: Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89 (1984).
30. Chenault, J. R., Kratzet, D. D., Rzepkowski, R. A., Goodwin, M. C: LH and FSH response of Holstein heifers to fertirelin acetate, gonadorelin and buserelin. Theriogenology 34, 81 (1990).
31. Sandow, J., Stoeckemann, K., Jerabek-Sandow, G.: Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues. J. Steroid. Biochem. Mol. Biol. 37, 925-931 (1990).
32. Somers, G. I., Lindsay, N.,Lowdon, B. M., Jones, A. E., Freathy, C., Ho, S., Woodrooffe, A. J., Bayliss, M. K., Manchee, G. R.: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drag. Metab. Dispos. 35, 1797-805 (2007).
33. Jonsson, B. A., Strand, S. E., Larsson, B. S.: A quantitative autoradiographic study of the heterogeneous activity distribution of different indium-111-labeled radiopharmaceuticals in rat tissues. J. Nucl. Med. 33, 1825-1833 (1992).
34. Segal-Abramson, T., Kitroser, H., Levy, J., Schally, A. V., Sharoni, Y.: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc. Natl. Acad. Sci. USA 89. 2336-2339 (1992).
35. Mullen, P., Bramley, T., Miller, W. R.: Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br. J. Cancer 63, 930-932 (1991).
36. Klijn, J. G. M., Beex Loux, V. A. M., Mauriac, L., van Zijil, J. A., Veyret, C., Wildiers, J., Jassern, J., Piccart, M., Burghouts, J., Becquart, D., Seynaeve, C., Mignolet, F., Duchateau, L.: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J. Natl. Cancer Inst. 92, 903-911 (2000).
37. Marclli, M. M., Moretti, R. M., Januszkicwicz-Caulier, J., Motta, M., Limonta, P.: Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients. Curr. Cancer Drug Targets 6. 257-269 (2006).
38. Mullen, P., Bramley, T., Menzies, G., Miller, B.: Failure to detect gonadotrophin-releasing hormone receptors in human benign and malignant breast tissue and in MCF-7 and MDA-MB-231 cancer cells. Eur. J. Cancer 29A, 248-252 (1993).
39. Vincze, B., Pályi, I., Gaál, D., Pató, J., Mora, M., Mezõ, I., Teplán, I., Seprõdi, J.: Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer cell lines. Cancer. Detect. Prev. 20, 146-152(1996).